Akebia Therapeutics, Inc.

DB:AX9 Stock Report

Market Cap: €609.9m

Akebia Therapeutics Management

Management criteria checks 2/4

Akebia Therapeutics' CEO is John Butler, appointed in Sep 2013, has a tenure of 11.67 years. total yearly compensation is $4.26M, comprised of 19.6% salary and 80.4% bonuses, including company stock and options. directly owns 0.64% of the company’s shares, worth €3.89M. The average tenure of the management team and the board of directors is 2.3 years and 6.4 years respectively.

Key information

John Butler

Chief executive officer

US$4.3m

Total compensation

CEO salary percentage19.58%
CEO tenure11.7yrs
CEO ownership0.6%
Management average tenure2.3yrs
Board average tenure6.4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has John Butler's remuneration changed compared to Akebia Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

-US$45m

Dec 31 2024US$4mUS$834k

-US$69m

Sep 30 2024n/an/a

-US$46m

Jun 30 2024n/an/a

-US$40m

Mar 31 2024n/an/a

-US$43m

Dec 31 2023US$3mUS$796k

-US$52m

Sep 30 2023n/an/a

-US$59m

Jun 30 2023n/an/a

-US$98m

Mar 31 2023n/an/a

-US$58m

Dec 31 2022US$3mUS$765k

-US$94m

Sep 30 2022n/an/a

-US$158m

Jun 30 2022n/an/a

-US$163m

Mar 31 2022n/an/a

-US$276m

Dec 31 2021US$3mUS$718k

-US$282m

Sep 30 2021n/an/a

-US$299m

Jun 30 2021n/an/a

-US$300m

Mar 31 2021n/an/a

-US$392m

Dec 31 2020US$6mUS$696k

-US$385m

Sep 30 2020n/an/a

-US$391m

Jun 30 2020n/an/a

-US$386m

Mar 31 2020n/an/a

-US$268m

Dec 31 2019US$4mUS$648k

-US$280m

Sep 30 2019n/an/a

-US$245m

Jun 30 2019n/an/a

-US$217m

Mar 31 2019n/an/a

-US$193m

Dec 31 2018US$3mUS$595k

-US$144m

Compensation vs Market: John's total compensation ($USD4.26M) is above average for companies of similar size in the German market ($USD1.25M).

Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.

CEO

John Butler (60 yo)

11.7yrs
Tenure
US$4,260,114
Compensation

Mr. John P. Butler, MBA, serves as Non-Executive Director at Wren Therapeutics Limited since 2023. He has been the Chief Executive Officer and President of Akebia Therapeutics, Inc. since September 2013 an...

Leadership Team

NamePositionTenureCompensationOwnership
John Butler
CEO, President & Director11.7yrsUS$4.26m0.64%
€ 3.9m
Erik Ostrowski
Chief Business Officerless than a yearUS$1.22mno data
Steven Burke
Senior VP of Research & Development and Chief Medical Officer5.8yrsUS$1.81m0.16%
€ 961.3k
Nicholas Grund
Senior VP & Chief Commercial Officer1.3yrsUS$1.85m0.017%
€ 105.6k
Richard Malabre
Chief Accounting Officer1.3yrsno data0.017%
€ 106.7k
Kimberly Garko
Senior VP & Chief Technical Officer1.3yrsno datano data
Tracey Vetterick
Vice President of Portfolio Strategy & Corporate Administration2.3yrsno datano data
Mercedes Carrasco
Senior Director of Investor & Corporate Communicationsno datano datano data
Carolyn Rucci
Senior VP of Legal3.3yrsno datano data
Meredith Bowman
Senior VP & Chief People Officer3.3yrsno datano data
2.3yrs
Average Tenure
60yo
Average Age

Experienced Management: AX9's management team is considered experienced (2.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
John Butler
CEO, President & Director11.8yrsUS$4.26m0.64%
€ 3.9m
Michael Rogers
Independent Director6.4yrsUS$142.83k0.037%
€ 223.0k
Adrian Adams
Independent Chairperson6.4yrsUS$165.33k0.051%
€ 313.0k
LeAnne Zumwalt
Independent Director4.3yrsUS$137.83k0.017%
€ 101.5k
Ronald Frieson
Independent Director3.5yrsUS$142.83k0.024%
€ 148.1k
Steven Gilman
Independent Director6.4yrsUS$135.33k0.033%
€ 202.4k
Cynthia Smith
Independent Director6.8yrsUS$142.83k0.036%
€ 221.1k
Myles Wolf
Independent Director5.1yrsUS$137.83k0.026%
€ 157.2k
6.4yrs
Average Tenure
64.5yo
Average Age

Experienced Board: AX9's board of directors are considered experienced (6.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/19 12:41
End of Day Share Price 2025/05/19 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Akebia Therapeutics, Inc. is covered by 21 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jonathan AschoffBrean Capital
Jonathan AschoffB. Riley Wealth
Julian HarrisonBTIG